WO2008016768A8 - Formulations phyto-œstrogéniques pour soulager ou prévenir des maladies neurodégénératives - Google Patents

Formulations phyto-œstrogéniques pour soulager ou prévenir des maladies neurodégénératives

Info

Publication number
WO2008016768A8
WO2008016768A8 PCT/US2007/073505 US2007073505W WO2008016768A8 WO 2008016768 A8 WO2008016768 A8 WO 2008016768A8 US 2007073505 W US2007073505 W US 2007073505W WO 2008016768 A8 WO2008016768 A8 WO 2008016768A8
Authority
WO
WIPO (PCT)
Prior art keywords
formulations
brain
phytoestrogen
select
women
Prior art date
Application number
PCT/US2007/073505
Other languages
English (en)
Other versions
WO2008016768A1 (fr
Inventor
Roberta Diaz Brinton
Liqin Zhao
Original Assignee
Roberta Diaz Brinton
Liqin Zhao
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roberta Diaz Brinton, Liqin Zhao filed Critical Roberta Diaz Brinton
Priority to EP07812924A priority Critical patent/EP2046325A1/fr
Priority to JP2009522917A priority patent/JP2009545605A/ja
Priority to AU2007281381A priority patent/AU2007281381A1/en
Priority to CA002659905A priority patent/CA2659905A1/fr
Publication of WO2008016768A1 publication Critical patent/WO2008016768A1/fr
Publication of WO2008016768A8 publication Critical patent/WO2008016768A8/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des compositions pharmaceutiques de phyto-œstrogènes sélectionnés et des procédés d'utilisation pour favoriser la santé neurologique et la prévention de la neurodégénérescence liée à l'âge, telles que la maladie d'Alzeihmer. Ces formulations de phyto-œstrogènes sélectionnés sont composées d'un nombre de molécules œstrogéniques d'origine végétale et/ou de leurs analogues structuraux et présentent une préférence de liaison à ERβ sur ERα et une activité agoniste dans le cerveau. Ces formulations de phyto-œstrogènes sélectives de ERβ traversent la barrière entre le sang et le cerveau et favorisent les mécanismes de neurotrophisme et de neuroprotection associés aux œstrogènes dans le cerveau, sans activer de mécanismes de prolifération dans les tissus reproducteurs et sont par conséquent exemptes d'autres aspects problématiques associés aux œstrogènes. Les formulations de phyto-œstrogènes sélectionnés sont thérapeutiquement utiles à la fois pour les femmes et pour les hommes pour entretenir la santé neurologique et prévenir un déclin cognitif lié à l'âge et des troubles neurodégénératifs, tels que la maladie d'Alzeihmer. Ces formulations sont administrées par voie entérale, transdermique, transmucosale, intranasale ou parentérale, dans un dosage efficace pour prévenir ou soulager un dommage neuronal, effectuent une régénération neuronale ou entretiennent la viabilité, augmentent l'expression de protéines anti-apoptotiques et/ou diminuent les indicateurs de la maladie d'Alzheimer. Les formulations contiennent, de préférence, des combinaisons de composés, et peuvent être formulées pour une administration quotidienne, entretenue, retardée ou hebdomadaire/mensuelle. Dans un mode de réalisation préféré, elles sont administrées à des femmes ménopausées ou post-ménopausées, préférablement tôt dans la ménopause.
PCT/US2007/073505 2006-08-02 2007-07-13 Formulations phyto-œstrogéniques pour soulager ou prévenir des maladies neurodégénératives WO2008016768A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP07812924A EP2046325A1 (fr) 2006-08-02 2007-07-13 Formulations phyto- strogéniques pour soulager ou prévenir des maladies neurodégénératives
JP2009522917A JP2009545605A (ja) 2006-08-02 2007-07-13 フィトエストロゲン製剤およびその使用
AU2007281381A AU2007281381A1 (en) 2006-08-02 2007-07-13 Phytoestrogenic formulations and uses thereof
CA002659905A CA2659905A1 (fr) 2006-08-02 2007-07-13 Formulations phyto-oestrogeniques pour soulager ou prevenir des maladies neurodegeneratives

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US81984906P 2006-08-02 2006-08-02
US60/819,849 2006-08-02
US88992007P 2007-02-14 2007-02-14
US60/889,920 2007-02-14
US94319007P 2007-06-11 2007-06-11
US60/943,190 2007-06-11

Publications (2)

Publication Number Publication Date
WO2008016768A1 WO2008016768A1 (fr) 2008-02-07
WO2008016768A8 true WO2008016768A8 (fr) 2008-06-12

Family

ID=38672818

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/073505 WO2008016768A1 (fr) 2006-08-02 2007-07-13 Formulations phyto-œstrogéniques pour soulager ou prévenir des maladies neurodégénératives

Country Status (5)

Country Link
EP (1) EP2046325A1 (fr)
JP (1) JP2009545605A (fr)
AU (1) AU2007281381A1 (fr)
CA (1) CA2659905A1 (fr)
WO (1) WO2008016768A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9604931B2 (en) 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
US9623021B2 (en) 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
CN101641013B (zh) 2007-01-22 2014-07-30 Gtx公司 核受体结合剂
US9333192B2 (en) 2010-02-15 2016-05-10 Sinoveda Canada, Inc Phytoestrogen product of red clover and pharmaceutical uses thereof
WO2013050930A1 (fr) * 2011-10-02 2013-04-11 Sinoveda Canada, Inc, Développement d'un produit de phytoestrogène de trèfle des prés pour la prévention ou le traitement de l'ostéoporose
JP6961694B2 (ja) * 2016-07-26 2021-11-05 オージオ・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー Ｓ−エコールを用いてアルツハイマー病を診断するおよび治療する方法
MX2019002673A (es) * 2016-09-12 2019-07-04 Hoffman Steven Composiciones y metodos para tratar demencia.
US20230330059A1 (en) * 2020-09-29 2023-10-19 Neurobionet, Inc. 3-phenyl-2h-chromene derivative and pharmaceutical composition for preventing or treating alzheimer's, containing same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994023716A1 (fr) * 1993-04-16 1994-10-27 Tufts University School Of Medicine Procede de traitement des symptomes menauposiques et premenstruels
EP0979074A4 (fr) * 1997-05-01 2003-07-09 Novogen Inc Traitement ou prevention des symptomes menopausiques et de l'osteoporose
JP2003521468A (ja) * 1999-03-17 2003-07-15 シグナル ファーマシューティカルズ， インコーポレイテッド エストロゲンレセプタを変調させるための化合物及び方法
US20040072765A1 (en) * 1999-04-28 2004-04-15 Novogen Research Pty Ltd. Cardiovascular and bone treatment using isoflavones
AUPQ008399A0 (en) * 1999-04-28 1999-05-27 Novogen Research Pty Ltd Cariovascular applications
WO2002051821A1 (fr) * 2000-12-22 2002-07-04 Astrazeneca Ab Composes therapeutiques
JP2006504409A (ja) * 2002-07-24 2006-02-09 チルドレンズ　ホスピタル　メディカル　センター 鏡像異性のエクオールを含有する組成物および製品、およびその製造方法
EP1750523B1 (fr) * 2004-03-17 2010-07-21 Nestec S.A. Compositions et methodes permettant de reduire ou de prevenir l'obesite

Also Published As

Publication number Publication date
AU2007281381A1 (en) 2008-02-07
JP2009545605A (ja) 2009-12-24
WO2008016768A1 (fr) 2008-02-07
EP2046325A1 (fr) 2009-04-15
CA2659905A1 (fr) 2008-02-07

Similar Documents

Publication Publication Date Title
WO2008016768A8 (fr) Formulations phyto-œstrogéniques pour soulager ou prévenir des maladies neurodégénératives
Mintziori et al. EMAS position statement: non-hormonal management of menopausal vasomotor symptoms
US8586629B2 (en) Composition for the treatment of oxidative stress
MY140576A (en) Cannabinoid active pharmaceutical ingredient for improved dosage forms
WO2018222923A1 (fr) Compositions pharmaceutiques comprenant du cannabidiol et du bêta-caryophyllène et leurs procédés d'utilisation
De Leo et al. Combined oral contraceptives in women with menstrual migraine without aura
HUP0204291A2 (hu) Hormonpótlási terápiához alkalmazható készítmény, amely drospirenont és ösztrogént tartalmaz
BRPI0507966A (pt) uso de meloxicam para o tratamento de doenças respiratórias em porcos
EP2331095A4 (fr) Certains inhibiteurs de kynurénine-3-monooxygénase, compositions pharmaceutiques, et procédés d'utilisation de ceux-ci
WO2008157537A3 (fr) Compositions et procédés d'utilisation pour traiter ou prévenir des troubles liés aux lipides
JP2009510084A5 (fr)
NZ579340A (en) Methods and compositions for promoting bone and joint health comprising berberine
AR049112A1 (es) Composiciones, metodos y kit, para el tratamiento de trastorno disforico premenstrual
WO2006063111A3 (fr) Formulations pharmaceutiques d'analogues de cytidine et derives
WO2007124250A3 (fr) Méthode de traitement des bouffées de chaleur par des préparations transdermiquea ou transmucosiques
WO2008116890A3 (fr) Nouvelles compositions pharmaceutiques
JP2011516425A5 (fr)
ATE421325T1 (de) Kombination von methylxanthinverbindungen und steroiden zur behandlung chronischer atemwegserkrankungen
JP2015524444A5 (fr)
HRP20130892T1 (hr) Farmaceutske formulacije i njihove upotrebe u lijeäśenju ženske seksualne disfunkcije
BR0316364A (pt) Combinação de terapia do câncer com um composto anticâncer ativado com gst e uma outra terapia anticâncer
UA92498C2 (ru) Каннабиноидно активный фармацевтический ингредиент для улучшенных дозированных форм
CN107951869A (zh) 含有大麻二酚的药物制剂及其应用
De Leo et al. Evaluation of combining kava extract with hormone replacement therapy in the treatment of postmenopausal anxiety
PE20060368A1 (es) Anticonceptivo hormonal conteniendo una combinacion de etinilestradiol y acetato de clormadinona

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07812924

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009522917

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2659905

Country of ref document: CA

Ref document number: 2007281381

Country of ref document: AU

NENP Non-entry into the national phase in:

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007812924

Country of ref document: EP

ENP Entry into the national phase in:

Ref document number: 2007281381

Country of ref document: AU

Date of ref document: 20070713

Kind code of ref document: A

NENP Non-entry into the national phase in:

Ref country code: RU